health visitor-led nondirective counselling (9, 10) , and nurse-facilitated support groups (11) have suggested that PPD is amenable to treatment. However, in 2001, a US National Institute of Mental Health expert panel concluded that "preventing postpartum depression is an important public health approach . . . that holds much promise" (12, p 81 ). This paper critically reviews the literature to determine the current state of scientific knowledge related to the prevention of PPD from a biological perspective.
Method

Search Strategy
Databases searched for this review include Medline, PubMed, Cinahl, PsycINFO, Embase, ProQuest, the Cochrane Library, and the World Health Organization Reproductive Health Library. As part of the quality assessment process, and to measure the capture rate of relevant references, the tables of contents of key journals were hand-searched for the past 2 years, and reference lists of included studies and relevant reviews were examined. The initial search was based on the identification of titles containing an appropriate combination and variation of such key words as postpartum or postnatal depression, maternal depression, prevention, and clinical trials. Finally, all abstracts related to the combination of the key words postpartum or postnatal depression and randomized controlled trials were reviewed to ensure that all potentially significant interventions were obtained. In total, approximately 30 abstracts were examined for inclusion suitability.
Inclusion and Exclusion Criteria
While there is considerable PPD research in progress, the literature review involved systematically searching for peerreviewed English-language articles published between January 1, 1966, and December 31, 2003 . Research studies that focused on PPD (for example, inception of depression within the first year postpartum) were reviewed; other childbirth-related mental health disorders (that is, pregnancy or postpartum anxiety, maternity blues, and puerperal psychosis) were not appraised. Finally, research studies evaluating preventive interventions must have incorporated a PPD outcome assessment beyond the first week postpartum to be included.
Methodology for Synthesis
Interventions were evaluated according to the published criteria used by the Canadian Task Force on Preventive Health Care (13) . Specifically, each preventive and treatment approach was evaluated and given a research design rating, as noted in Table 3 (see footnote a). Following this rating, studies were given a quality rating (that is, a rating of internal validity), as shown in Table 3 (see footnote b) .
After the quality-of-evidence assessment was complete, each strategy was further classified to determine clinical practice recommendations, according to the grading scheme shown in Table 3 (see footnote c).
Results
For this critical review, 7 preventive studies that met inclusion criteria were examined. Study summaries and limitations are presented in Tables 1 and 2 , and the clinical practice recommendations drawn from the Canadian Task Force methodology are outlined in Table 3 .
Pharmacologic Interventions (Table 1 ) Antidepressant Medication. Women who have suffered from one episode of PPD are justifiably apprehensive regarding a recurrence with future births. In Davidson and others' naturalistic follow-up study of 20 women with initial episodes of PPD who went on to have 33 more pregnancies, 6 mothers (30%) developed 8 subsequent incidences of PPD, suggesting that the risk of subsequent PPD occurring among women is approximately 1 in 4 (14) . It has been hypothesized that administration of AD medication to asymptomatic women in the immediate postpartum period may prevent recurrent episodes of PPD. To determine the efficacy of prophylactic AD medication, Wisner and colleagues conducted an open quasi-experimental study at a US outpatient clinic treating pregnant and postpartum women with mood disorders (15) . Twenty-three pregnant women with at least one previous postpartum episode according to DSM-III-R criteria for major depression were recruited. Postpartum monitoring for recurrence of depressive symptoms (n = 8) was compared with postpartum monitoring plus AD treatment with either a previously effective AD medication or nortriptyline (n = 15). The first dose was given within 24 hours of childbirth, and the recurrence of PPD was monitored via psychiatric examinations for the first 12 weeks postpartum. Only 1 (6.7%) mother who elected postpartum monitoring plus prophylactic AD medication suffered a recurrence, compared with 5 (62.5%) women who elected postpartum monitoring (P = 0.009). However, 10 out of 23 participants were treated with ADs during their current pregnancy; this included 7 women (47%) in the prophylactic group and 3 women (37%) in the monitoringonly group. While AD dosages were tapered off in the 2 weeks preceding delivery to recommence use in the intervention group, the residual effect of this antenatal AD use on PPD reoccurrence is unknown; thus, study conclusions are limited.
Advancing their initial work, Wisner and colleagues conducted a double-blind RCT to evaluate the efficacy of nortriptyline in the prevention of recurrent PPD (16) . A total of 51 women without depression and with at least 1 previous episode of PPD meeting research diagnostic criteria were recruited antenatally and were randomly assigned to receive either nortriptyline or placebo in the immediate postpartum period. They assessed each mother for 20 sequential weeks, using the Hamilton Depression Rating Scale (HDRS). No significant group difference was found: 6 (23.1%) mothers who took nortriptyline prophylactically and 6 (24%) mothers who received placebo suffered a recurrence (P = 1.00). Consistent with previous research, the rate of recurrence was approximately 1 in 4. The results from this study suggest that nortriptyline does not confer additional preventive efficacy beyond that of placebo. (Table 1) The maternal pituitary gland, thyroid and parathyroid glands, and pancreatic cells all increase in size during pregnancy. In addition, there are increases in gluocorticoids, mineralocorticorids, rennin, angiotensin, and androgens (17) . The primary endocrine abnormalities can be accompanied by mood changes (for example, hyper-and hypothroidism and diabetes mellitus), and it is not surprising that various hormonal theories have been proposed as explanations for PPD.
Hormonal Interventions
One of the hormonal hypotheses that have been put forward relates to the rapidly decreasing levels of sex hormones, particularly estrogen and progesterone. However, despite the fall in circulating progesterone and estrogen in the immediate postpartum period, researchers have failed to consistently demonstrate a link between hormone levels and PPD (18, 19) . For example, O'Hara and colleagues compared hormone concentrations in childbearing women who suffered from depression with concentrations in those who did not. Frequent assays of prolactin, progesterone, estradiol, free and total estriol, and cortisol and urinary free cortisol during pregnancy and immediately postpartum revealed few differences (20) . However, failure to demonstrate endocrinological evidence of hormone deficiencies does not exclude them as etiologic factors, because both estrogen and progesterone have psychoactive Less than 25% of eligible women approached agreed to trial participation EPDS = Edinburgh Postnatal Depression Scale; HDRS = Hamilton Depression Rating Scale; RCT = randomized controlled trial; MADRS = Montgomery-Asberg Depression Rating Scale properties. Thus, several researchers have evaluated diverse hormonal prophylaxis.
Estrogen Therapy.
In an open-label US study, 7 women with a history of postpartum psychosis and 4 with a history of PPD were consecutively treated with high-dosage oral estrogen immediately following delivery (21) . None of the women had a history of nonpuerperal affective disorder, and all were affectively well throughout the current pregnancy. The intervention consisted of oral premarin daily in decreasing dosages over 4 weeks. A high dosage was chosen in the first few days postpartum to approximate term pregnancy estradiol levels before a gradual taper, which was designed to cushion the usual fall to follicular-phase estradiol levels. During the first 5 days postpartum, DSM-III-R checklist was used to evaluate women daily for mood and neurovegetative symptoms. Follow-up was conducted via clinical interview at 1, 3, 6, and 12 months postpartum. All but 1 participant remained without depression and required no treatment with psychotropic medications during the 1-year follow-up period. The low rate of relapse in this small study suggests that further research is warranted to assess the prophylactic ability of oral estrogen in the immediate postpartum period among mothers at risk for a reoccurrence of postpartum affective disorders. However, research has failed to demonstrate a consistent relation between PPD and breast-feeding (which induces lower estrogen levels), which clearly challenges the claim that estrogen therapy will be a useful preventive approach (22) .
Progesterone Therapy. Dalton popularized the prophylactic use of progesterone for PPD (23, 24 For abbreviations see Table 1 BDI = Beck Depression Inventory; GHQ = General Health Questionnaire some researchers to have a hormonal etiology similar to PPD, found no significant differences between treatment and placebo groups (26, 27) . However, synthetic progestogens have been implicated in depression among women who use them for contraception (28, 29) . Thus, there is evidence to support the possibility that progesterone may either reduce or increase the risk of PPD.
To address this question, Lawrie and colleagues conducted a double-blind RCT to determine the effect of a long-acting progestogen contraceptive, norethisterone enanthate, administered postnatally upon development of PPD (30) . A total of 180 postpartum women using a nonhormonal method of contraception were recruited from a tertiary hospital in Johannesburg, South Africa. Women were randomly allocated within 48 hours of delivery to either a progestogen group (receiving a single dose of norethisterone enanthate 200 mg by intramuscular injection; n = 90) or a placebo group (receiving 200 mg of normal saline placebo by intramuscular injection; n = 90).
Mothers completed the Edinburgh Postnatal Depression Scale (EPDS) and the Montgomery-Asberg Depression Rating Scale (MADRS) as part of a clinical interview at 1, 6, and 12 weeks postpartum. Compared with the placebo group, women receiving the progestogen injection were at significantly greater risk of developing depressive symptomatology by 6 weeks postpartum. For women in the intervention group, the relative risk of scoring above 9 on the MADRS and above 11 on the EPDS was 2.56 (95% CI, 1.26 to 5.18) and 3.04 (95%CI, 1.52 to 6.08), respectively. No significant group differences were found at 12 weeks; researchers hypothesized this was related to the fact that only a single dose was administered. The results from this well-conducted trial incorporating good randomization and blinding methods a power analysis, intent-to-treat data analysis, and valid measures, indicate that progestogen contraceptives should be used with caution in the postpartum period.
Thyroid Function (Table 2)
Research suggests that women who are positive for thyroid antibodies in pregnancy are at risk of developing PPD (31, 32) . In the UK, a randomized, double-blind, placebo-controlled trial was conducted to test the hypothesis that stabilizing thyroid function postnatally by administering daily thyroxine reduces the rate of occurrence and severity of associated depression: 100 microg of thyroxine or placebo was given daily to 446 thyroid antibody-positive women (342 of whom were compliant) from 6 to 24 weeks postpartum (33) . Maternal mood and thyroid status were assessed at 4 weekly intervals. There was no evidence that thyroxine had any effect on the occurrence of depression. This well-conducted trial provides good preliminary evidence that the higher rate of PPD among thyroid antibody-positive women is not corrected by daily administration of thyroxine. The researchers also suggested that the negative findings indicate that PPD is more likely associated with known risk factors, such as negative life events, than with abnormal biochemical thyroid function.
Other Interventions (Table 2 ) Docosahexanoic Acid (DHA). Epidemiologic studies have shown that populations with high intakes of omega-3 fatty acids have lower rates of depression than do populations with low consumption of omega-3 fatty acids (34) . Plasma concentrations of DHA, an omega-3 fatty acid, gradually decrease during the late stages of pregnancy and remain low for some time during the postpartum period, especially among women who are breast-feeding (35) . Because concentration of DHA is high in the structural lipids of brain cell membranes, including those of the synaptic terminals that are responsible for neurochemical transmission, (36) it has been postulated that brain DHA levels also may be low during late pregnancy and early postpartum and that these low levels of DHA may contribute to the emergence of PPD (37) . To assess the influence of DHA status among women with and without PPD, the contents of DHA and its status indicator, n-6 docosapentanoic acid (n-6DPA, 22:5n-6), were measured in the plasma phospholipids of 112 women at delivery and at 32 weeks postpartum (38) . At this later time, the EPDS was completed to define "possibly depressed" (EPDS score > 9) and "nondepressed" (EPDS score < 10) women. The results demonstrated that the postpartum increase of the functional DHA status, expressed as the ratio DHA/n-6DPA, was significantly lower in the "possibly depressed" group, compared with the "nondepressed" group (2.34 [SD 5 .56] vs 4.86 [SD 5.41]), respectively; odds ratio [OR] 0.88, P = 0.03). Breast-feeding women were not more predisposed to develop depressive symptoms than were nonbreast-feeding women. From this observation, it seems that there is less availability of DHA in the postpartum period among women developing depressive symptoms.
To determine the effect of DHA supplementation on plasma phospholipid DHA content and indices of depression, 138 pregnant US women who planned to breast-feed their infants were randomly assigned in double-blind fashion to receive either DHA (approximately 200 mg daily) or placebo for the first 4 months postpartum (39) . Major outcome variables included plasma phospholipid fatty acid patterns and scores on the Beck Depression Inventory (BDI). Structured Clinical Interview for DSM-IV Axis I Disorders-Clinician Version (SCID-CV) scores and EPDS scores were obtained from subgroups of the total population. Plasma phospholipid contents of DHA at baseline were 3.15 (SD 0.78) and 3.31 (SD 0.70) (mg/dL of total fatty acids) in the DHA and placebo groups, respectively. After 4 months, the plasma phospholipid DHA content of the DHA group was 8% higher (3.40 mg/dL [SD 0.97]), whereas that of the placebo group was 31% lower (2.27 mg/dL [SD 0.87]). Despite the higher plasma phospholipid DHA content of the supplemented group, there was no difference between groups in either self-rating or diagnostic measures of depression. The results suggest that, while DHA supplementation after delivery prevents the usual decline in plasma phospholipid DHA content among women who breast-feed, it does not influence self-ratings or diagnostic measures of depression.
Calcium Supplementation. Evidence that calcium supplementation may play a beneficial role in affective disorders comes from studies evaluating the effects of dietary calcium on premenstrual syndrome (PMS) (40) (41) (42) . For example, Thys-Jacobs and Alvir (43) reported a significant drop in total and ionized calcium at the midpoint of the menstrual cycle that coincided with an increase in estradiol. They also found that women with PMS and control subjects showed differences in total serum calcium across the menstrual cycle. These data suggest that calcium metabolism is influenced by the menstrual cycle and indicate that women with PMS may have an underlying deficit in calcium metabolism that is exacerbated by fluctuations in gonadal hormones. While this research links disturbance in calcium metabolism and PMS, it does not explain how calcium influences negative affect. To determine the effect of calcium carbonate on the prevention of PPD, women from Portland, Oregon, and Albuquerque, New Mexico, participated in a randomized, double-blind, placebocontrolled trial for the prevention of preeclampsia and completed the EPDS at 6 and 12 weeks postpartum (44). At 6 weeks, the proportion of EPDS scores ³ 14 was 11% (16/150) for the calcium group from Portland and 18% (26/143) for the placebo group. The proportions from Albuquerque were 24% (10/42) vs 21% (8/39) (P > 0.05). At 12 weeks, only 5.7% (7/123) of the calcium group had an EPDS score >14, compared with 15.3% (19/124) of the placebo recipients (P = 0.01). The results demonstrate that oral calcium supplementation reduced the point prevalence of PPD significantly at 12 weeks and marginally at 6 weeks.
Discussion
The long-term consequences of PPD suggest that preventive approaches are warranted. The manipulation of a given risk factor may decrease the associated likelihood of developing PPD. The most obvious is to decrease the amount of exposure to a given risk factor or, alternatively, to reduce the strength or mechanism of the relation between the risk factor and PPD (45) . However, translating risk factor research into predictive screening protocols and preventive interventions has met with limited success, as complex interactions of biopsychosocial risk factors with individual variations need to be contemplated. The 7 studies examined in this review reflect a broad range of biological approaches. Although theoretical justifications for many of these approaches have been presented, methodological limitations render intervention efficacy equivocal; scant evidence is available to guide practice or policy recommendations (Table 3) . a I = evidence from randomized controlled trial(s); II-1 = evidence from controlled trial(s) without randomization; II-2 = evidence from cohort or case-control analytic studies, preferably from more than one centre or research group; II-3 = evidence from comparisons between times or places with or without the intervention; dramatic results in uncontrolled experiments could be included here; III = opinion of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees. b Good = a study, including metaanalyses and systematic reviews, that meets all design-specific criteria well; Fair = a study, including metaanalyses and systematic reviews, that does not meet, or does not clearly meet, at least one design-specific criterion but that has no known "fatal flaw"; Poor = a study, including metaanalyses and systematic reviews, that has at least 1 design-specific "fatal flaw" or an accumulation of lesser flaws to the extent that the results of the study are not deemed able to inform recommendation. c A = there is good evidence to recommend this approach; B = there is fair evidence to recommend this approach; C = the existing evidence is conflicting and does not allow making a recommendation for or against use of this approach, though other factors may influence decision making; D = there is fair evidence to recommend against this approach; E = there is good evidence to recommend against this approach; I = there is insufficient evidence (in quantity and [or] quality) to make a recommendation, though other factors may influence decision making.
Only 2 small US studies have evaluated the efficacy of prophylactic AD medication (nortriptyline), and it is unknown whether the conflicting results are related to methodological limitations, inadequate drug mechanism, or intervention or approach ineffectiveness. Because of the poor quality of the evidence, the effect of pharmacologic interventions in the prevention of PPD is unclear, and this approach cannot be recommended for clinical practice. Well-conducted RCTs are needed and should include interventions that evaluate commercially available ADs from diverse drug categories.
Similarly, the effectiveness of hormonal interventions also needs to be rigorously examined. While the low rate of relapse in Sichel's study (21) suggests further research in the prophylactic ability of oral estrogen is warranted, safety issues associated with administering such a high dosage need to be examined, particularly for breast-feeding women. To delineate the potential effects of hormonal changes on depression and relapse risk, research efforts should expand to include investigations that examine women's hormonal levels across the perinatal period from pregnancy until the resumption of normal menstrual cycles. Currently, the neurochemical mechanism preventing affective relapse in high-risk women is only hypothesized, and future research is needed to clarify the role of prophylactic agents. Notably, one well-designed trial suggested that synthetic progestogens increased the risk of developing depressive symptomatology (30) . There is fair evidence to support the recommendation that long-acting progestogen contraceptives should not be given in the postpartum period (46) . Further, it is conceivable that natural progesterone has an AD effect, while synthetic progestogens, which also have strong androgenic activity, are depressogenic. Research to distinguish such differences is warranted.
One study was found evaluating the effect of DHA supplementation on maternal mood. While the plasma phospholipid DHA content of the placebo group decreased by 31% and that of the DHA supplementation group increased by 8%, resulting in a 50% higher DHA content in the supplemented group, no significant group differences in PPD rates were found. Perhaps a higher dosage of DHA supplementation may create brain membrane alterations that are capable of enhancing mood. Alternatively, DHA supplementation during pregnancy may reduce the gradual decline in plasma phospholipid DHA content, thereby reducing its impact on mood during the postpartum period.
Harrison-Hohner and colleagues (44) found that, while women who supplemented with calcium during pregnancy showed a significantly lower incidence of PPD at 12 weeks, serious methodological limitations existed, including a response rate as low as 28.7% and important sample differences between the 2 sites. Further, the study was a secondary analysis of an RCT that examined the effect of calcium supplementation on preeclampsia. As such, the prophylactic effect of calcium remains unknown. It is hypothesized that the link between calcium and negative affect may be related to calcium as an intracellular messenger. For example, cytosolic calcium concentration plays a critical role in stimulusresponse coupling in various tissues, including the nervous system, where the influx of calcium into the cell is proportional to the release of neurotransmitters (47) . Thus, disturbances of intracellular calcium regulation could have extensive consequences for cellular function, which may modify mood. Further research is needed to examine whether calcium-mediated modification of neurohormonal activity during pregnancy and the postpartum period alters the trajectory of prenatal and postnatal neurohormonal changes and decreases the vulnerability to PPD.
While this review demonstrates that no specific biological approach can be strongly recommended for clinical practice, many explicit research implications have been highlighted. To most efficiently conduct this research, there continues to be a need for further interdisciplinary networking among investigators with complementary research interests. In addition, to further address PPD as a public health problem, it is critical to include ethnically and socioeconomically diverse women in research efforts examining the differences among depression symptoms and response rates to interventions. Résultats : Sept études qui satisfaisaient aux critères ont été examinées. Elles portaient sur l'utilisation de médicaments dont les antidépresseurs, la thérapie à l'oestrogène et à la progestérone, la thérapie thyroïdienne, l'acide docasahexanoïque et les suppléments de calcium. Bien que ces interventions aient été examinées plus rigoureusement pour la dépression non liée à l'accouchement, les limites méthodologiques des études rendent l'efficacité de l'intervention équivoque pour la DPP, fournissant ainsi de fortes données probantes limitées pour orienter des recommandations sur la pratique ou la politique.
Conclusions :
Malgré la hausse très marquée d'intérêt pour ce domaine, de nombreuses questions demeurent sans réponse, ce qui a plusieurs implications pour la recherche.
